Table 3 Clonal evolution at the time of progression to therapy-related myeloid neoplasm.
From: Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms
UPIN | t-CC to t-MN* | Cytogenetics at t-CC | # PV at t-CC | PV at t-CC (%VAF) | Cytogenetics at t-MN | # PV at t-MN | PV at t-MN (%VAF) | Summary |
|---|---|---|---|---|---|---|---|---|
1012 | 6.6 | 46,XY,del(7)(p15)[20] | Not performed | 46,XY,del(7)(p15)[20] | 0 | None | No change | |
1067 | 3.5 | 46, XX | 2 | BCOR (23%), U2AF1 (26%) | 46, XX | 3 | BCOR (36%), U2AF1 (45%), NRAS (43%) | Clonal evolution |
1132 | 3.0 | 47,XY, + 21[3]/46, XY[17] | Not performed | 47,XY, + 21[7]/46,XY[13]. | 2 | SRSF2 (44%), U2AF1 (36%) | No change | |
1142 | 98.7 | Trisomy 8 | Not performed | 47,XX, + 8[6]/46,XX[14] | Not performed | No change | ||
1724 | 47.8 | 46, XY | 2 | DNMT3A (8%), RUNX1 (48%) | 46,XX,del(13)(q12q14)[7]/46,XX[13] | 0 | None | Clonal evolution |
2004 | 33.1 | 46,XY,del(4)(q21q31),t(7;20)(q22;q13.1)[4]/ 46,XY[16]. | 0 | None | 45,XY,del(5)(q22q31),add(7)(q22),-14,add(18)(q21), add(19)(p13.1)[18]/ 45,XY,del(5)(q22q31),add(6)(p23),-18[2]. | 2 | TP53 (25%) CEBPA (7%) | Clonal evolution |
2043 | 6.1 | 47,XY, + 8[11]/46,XY[9] | Not performed | 47,XY, + 8[8]/46,XY[12] | 6 | ASXL1 (46%), BCOR (65%), EZH2 (44%) EZH2 (50%), RUNX1 (13%), TET2 (44%) | No change | |
2052 | 8.1 | 46, XY | 2 | IDH1 (33%), SRSF2 (27%) | 46, XY | Not performed | No change | |
2057 | 5.4 | 46, XY | 2 | TP53 (5.5%), TP53 (7.5%) | 46,XY,del(7)(q22)[11]/47,idem,+21[5]/46,XY[4] | 0 | None | Clonal evolution |
